Studies show that CYP2D6 genotype does not predict tamoxifen benefit

Two studies published March 6 in the Journal of the National Cancer Institute provide insights about the CYP2D6 genotype in postmenopausal breast cancer patients and represent a major step forward in understanding the usefulness of CYP2D6 testing for deciding whether or not a patient should receive adjuvant tamoxifen for treatment of early-stage breast cancer. Both studies found that CYP2D6 genotypes that were indicative of reduced activity of enzymes that metabolize tamoxifen did not predict clinical responsiveness to adjuvant tamoxifen therapy among postmenopausal women with early-stage breast cancer. Researchers participating in the two studies included scientists from the Dana-Farber Cancer Institute in Boston, Emory University School of Medicine in Atlanta, and the University of Michigan Comprehensive Cancer Center.

Click here to read full press release.

###

Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.